Contract Research Organization Market Procurement Intelligence, Supplier Intelligence, Supplier Ranking, Pricing & Cost Structure Intelligence, Best Practices, Engagement Model, Low & Best Cost Country, Day One Analysis Report, 2020 - 2025

Every organization and its procurement team wants to negotiate the best deal while procuring a set of products or services. Rate benchmarking uses price/cost comparison of more than one set of products/services to analyze the most efficient combination that will help the procurement team to get the optimum rate.

The geographic location where the clinical trial is been conducted plays a major role while analyzing the rate benchmarking of a CRO service. In our research, we have analyzed the rates of oncology clinical trials, as it is the most common type of clinical trial across the globe. For instance, breast cancer phase 3 clinical trial cost in India and China is 90% lower than the clinical trial cost of the U.S and the U.K. Conducting clinical trials via CRO in Western European and North American countries needs double the cost of conducting clinical trials in APAC. However, for the clinical trial of critical diseases, the trial majorly happens in developed countries of Western Europe and North America, as the APAC region lacks the number of skilled professionals to conduct these types of clinical trials.

To gain a comprehensive understanding of the other aspects of rate benchmarking, please subscribe to our services for the complete report.

Labor is one of the key cost components incurred while offering a product or service. Understanding the pricing structure of salary is important for organizations in selecting the appropriate supplier and building a good negotiation strategy. It is also an important factor in determining whether the category under focus should be outsourced or built in-house.

Our research indicates that Principal Investigators and Clinical Research Co-coordinators of IQVIA earn 10%-15% higher salaries than Principal Investigators and Clinical Research Co-coordinators of Covance and Syneos Health. However, Syneos Health and Covance have a 10% YoY increment compare to IQVIA’s 7%-8%. We have also found that IQVIA and Covance offer 36% higher bonuses to principal investigators compare to Syneos Health

It is cumbersome for any organization to continuously track the latest developments in their supplier landscape. Our newsletter service helps them remain updated, to avoid any supply chain disruption which they may face, and keep a track of the latest innovations from the suppliers. Outsourcing such activities help clients focus on their core offerings. Our research on the CRO market has identified the following developments:

In July 2021, Parexel announced that it will be purchased by Goldman Sachs Asset Management and EQT Private Equity for USD8.5 billion. This acquisition will not change the overall business of Parexel, rather the acquirers will invest in Parexel’s real-world evidence, decentralized clinical trials, biostatistics, and data management systems.

In February 2021, ICON announced the acquisition of its rival PRA Health Sciences for USD12 billion. Before this deal, ICON ranks as the sixth-largest CRO measured by revenue while PRA is the fifth largest. This deal made the combined company the second-largest CRO, trailing the approximately USD5.8 billion that IQVIA generates from contract services.